Hugel, Inc. (KOSDAQ: 145020)

Market Cap	2.76T
Revenue (ttm)	343.49B
Net Income (ttm)	111.17B
Shares Out	10.97M
EPS (ttm)	9,741.39
PE Ratio	25.82
Forward PE	29.18
Dividend	n/a
Ex-Dividend Date	n/a

Volume	30,094
Open	251,500
Previous Close	251,500
Day's Range	251,000 - 258,000
52-Week Range	117,400 - 295,500
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 7, 2024

About Hugel

Hugel, Inc. develops and manufactures biopharmaceuticals in South Korea and internationally. The company offers Botulinum Toxin, a white injectable dry powder in a transparent glass vial for use in the treatment of positive essential eyelid convulsion in adults over 18 years of age; improvement of severe lasso wrinkles associated with corrugator muscles and/or procerus muscle activities in adults aged between 18 and 65; treatment of upper limb stroke; and treatment of dynamic equinus foot deformity in children with cerebral palsy over 2 years o...

• Industry: Pharmaceutical Preparations
• Founded: 2001
• Employees: 594
• Stock Exchange: KOSDAQ
• Ticker Symbol: 145020

Financial Performance

In 2023, Hugel's revenue was 319.70 billion, an increase of 13.50% compared to the previous year's 281.68 billion. Earnings were 93.08 billion, an increase of 62.35%.